SCHEMBL7658785

SCHEMBL7658785

CCCCC(NC(=O)c1cccc(NS(=O)(=O)c2ccc3ccccc3c2)c1)C(=O)CNC(C)=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.45
LMNA P02545 1/20 0.45
GAA P10253 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
AKR1C3 P42330 1/20 0.45
GGPS1 O95749 1/20 0.44
PLAU P00749 1/20 0.44
HDAC3 O15379 1/20 0.43
HDAC4 P56524 1/20 0.43
HDAC1 Q13547 1/20 0.43
HDAC7 Q8WUI4 1/20 0.43
HDAC2 Q92769 1/20 0.43
HDAC10 Q969S8 1/20 0.43
HDAC11 Q96DB2 1/20 0.43
HDAC8 Q9BY41 1/20 0.43
HDAC6 Q9UBN7 1/20 0.43
HDAC9 Q9UKV0 1/20 0.43
HDAC5 Q9UQL6 1/20 0.43
KAT6A Q92794 5/20 0.42
AR P10275 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7659849 0.93 AKR1C3 (0.47) ALDH1A1LMNAGAASMN1; SMN2AKR1C3
SCHEMBL7654043 0.91 ALDH1A1 (0.54) ALDH1A1LMNAGAASMN1; SMN2AKR1C3
SCHEMBL7665441 0.90 EGFR (0.46) LMNASMN1; SMN2PLAUHDAC3HDAC4
SCHEMBL7427436 0.90 AKR1C3 (0.45) ALDH1A1LMNAGAASMN1; SMN2AKR1C3
SCHEMBL7680584 0.89 AKR1C3 (0.48) ALDH1A1LMNAGAASMN1; SMN2AKR1C3
SCHEMBL7695396 0.87 AKR1C3 (0.48) ALDH1A1LMNAGAASMN1; SMN2AKR1C3
SCHEMBL7665000 0.86 ALDH1A1 (0.52) ALDH1A1LMNAGAASMN1; SMN2AKR1C3
SCHEMBL7661487 0.84 EGFR (0.47) PLAUHDAC3HDAC4HDAC1HDAC7
SCHEMBL7388646 0.82 MEN1 (0.49) ALDH1A1GAASMN1; SMN2MEN1KMT2A
SCHEMBL7690188 0.81 EGFR (0.48) PLAUHDAC3HDAC4HDAC1HDAC7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6436925-B1 BETTER ABLE TO CROSS MEMBRANES; INHIBITORS OF CYSTEINE PROTEASES LIKE CALPAIN I AND II AND CATHEPSIN B AND L, CAN THUS BE USED TO CONTROL DISEASES ASSOCIATED WITH AN ELEVATED ACTIVITY OF CALPAIN ENZYMES OR CATHEPSIN ENZYMES ABBOTT LABORATORIES 2002-08-20 US disclosed